- Palisade Bio ( NASDAQ: PALI ) on Friday said it had entered into a registered direct offering and concurrent private placement for 1.05M shares of its common stock at a purchase price of $2.375/share.
- Shares of the micro-cap clinical stage biopharma surged 28.6% to $4.14 in premarket trading.
- PALI intends to use the net proceeds from the financing for working capital and general corporate purposes, the company said in a statement .
- The offering is expected to close on or about Jan. 4, 2023.
For further details see:
Palisade Bio stock jumps ~29% on $2.5M direct offering, private placement